Newsroom

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into Spain and the appointment of María Baquerizo López-Quectuy as Spain Country Manager. This follows a €32 million Series A investment by MVM Partners announced in November 2025 and the recent entry to France. Avanzanite’s continues to build its integrated European platform designed to accelerate access to...

RIYADH, Saudi Arabia--(BUSINESS WIRE)--Arcova enters Saudi Arabia with its first regional cybersecurity contract, supporting Middle East growth in cyber and AI services....

LONDON--(BUSINESS WIRE)--Cursor, the leading multi-model AI coding platform, today announced the establishment of dedicated teams to serve the EMEA region. The expansion responds to regional momentum, with EMEA revenue tripling quarter over quarter this year. The Cursor EMEA team will support a rapidly expanding customer base that includes British Airways, BP, Deliveroo, Nokia, Sanofi and many other leading enterprises across the region. Cursor expects to grow its EMEA headcount to approximatel...

CAMBRIDGE, England--(BUSINESS WIRE)--British computing technology company Signaloid will preview its C0-ASIC for physical AI this week at Bosch Connected World, taking place from 10th-11th June, in Berlin. Designed for robotics, industrial automation, and probabilistic AI workloads, the ASIC is projected to deliver up to 1000× better performance-per-Watt than existing state-of-the-art approaches. Signaloid’s distribution-extended compute hardware (UxHw®) is already available for use in physical...

BOSTON & BRISBANE, Australia--(BUSINESS WIRE)--AdvanCell, azienda radiofarmaceutica di fase clinica che sviluppa terapie alfa mirate innovative contro il cancro, oggi ha annunciato la nomina di Justyna Kelly a Direttore tecnologico (CTO) e François Gaudet a Direttore scientifico (CSO), ampliando il team di leadership esecutiva della società negli Stati Uniti, mentre continua a potenziare la propria presenza negli Stati Uniti e a promuovere la sua crescente pipeline di terapie alfa mirate innova...

BOSTON & BRISBANE, Australië--(BUSINESS WIRE)--AdvanCell, een producent van radiofarmaca in klinische fase die innovatieve doelgerichte alfatherapieën ter bestrijding van kanker ontwikkelt, kondigde vandaag de benoeming aan van Justyna Kelly tot Chief Technology Officer (CTO) en François Gaudet tot Chief Scientific Officer (CSO). Met deze benoemingen wordt het bestuursteam van het bedrijf in de V.S. uitgebreid, nu het bedrijf zijn capaciteiten in de V.S. verder op schaal brengt, en bevorderen d...

香港--(BUSINESS WIRE)--（ビジネスワイヤ） -- オアシス・マネジメント・カンパニー・リミテッド（以下「オアシス」または「当社」といいます。）は、株式会社KADOKAWA（証券コード：9468 JT）（以下「KADOKAWA」または「同社」といいます。）の株式を保有するファンドの運用会社です。オアシスは本日、公正取引委員会（以下「公取委」といいます。）が、特定受託事業者に係る取引の適正化等に関する法律、いわゆるフリーランス保護法違反を理由として、KADOKAWAに対し再度の勧告を行う方針である報道を受け、以下の声明を発表いたします。 報道によれば、公取委は、KADOKAWAが雑誌製作の関連業務をフリーランスのライター、スタイリスト、イラストレーター等に委託する際、報酬の支払期日を含む取引条件を書面で明示していなかったこと、また同社による報酬支払の遅延についても違反を認定する見通しであるとされています。対象のフリーランスは100名を超える可能性があり、当該違反行為は2024年冬以降に行われたと報じられています。KADOKAWAは、公取委による調査を受けていることを認め...

HONG KONG--(BUSINESS WIRE)--Oasis Management Company Ltd. (“Oasis”), the investment manager to private funds that own shares in KADOKAWA CORPORATION (“KADOKAWA” or the “Company”), today issued the following statement in response to media reports that the Japan Fair Trade Commission (“JFTC”) intends to issue another recommendation against KADOKAWA for violations of the Act on Ensuring Proper Transactions Involving Specified Entrusted Business Operators, widely known as the Freelance Protection A...

HANOVER, Md.--(BUSINESS WIRE)--Ciena today announced that it has priced its private offering of $2.5 billion aggregate principal amount of 0.00% convertible senior notes due 2031....

RAICHUR (India) y BARCELONA (España)--(BUSINESS WIRE)--Shilpa Biocare Pvt Ltd, una filial de Shilpa Medicare Limited (BSE/NSE: SHILPAMED), acaba de firmar una alianza estratégica de capital con Gate2Brain, S.L., una empresa de biotecnología especializada en terapias para el sistema nervioso central. Shilpa se convierte en accionista estratégico y socio en materia de química, fabricación y controles (CMC) y asuntos regulatorios para G2B-002, el programa principal de Gate2Brain dirigido a los cán...